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Abstract 
To confidently diagnose and treat Lyme disease, the clinician must first understand the 
natural history of this disease, especially its protean early manifestations. Emergency 
physicians, primary care physicians, and other providers need to be vigilant in terms of 
the timely recognition of erythema migrans (EM), the unique marker of early localized 
stage 1 disease. The classic EM, originally described as a slowly expanding bull's eye 
lesion, is now recognized to be present in only the minority of cases (9%); the dominant 
morphologic lesion of EM is now recognized to be the diffusely homogenous red plaque 
or patch, which occurs in over 50% of cases. This update will define the current 
morphologic features of early Lyme disease, the indication for serologic studies, and the 
most recent treatment guidelines, including therapeutic pitfalls.  
Introduction 
This article focuses exclusively on the most recent diagnostic criteria and evidence-based 
treatment of early Lyme disease (LD). The recognition of the early manifestations of LD 
by Emergency and Primary Care Physicians, as well as other caregivers, is essential, as 
this condition can progress to a multi-system disease if left untreated (1). One of the 
reasons for misdiagnosis of early LD is a lack of understanding of the protean 
morphologic features of erythema migrans (EM), the unique marker of early localized 
stage 1 disease (2). Delaying the diagnosis of EM because the lesion does not conform to 
a bull's eye and relying on serologic studies are often the main reasons why physicians 
“miss the mark” in timely recognition of early LD. Likewise, antibiotic selection specific 
for the treatment of this stage is crucial, or the disease can progress, as occurred in the 
presented case (3).  
Case Report 
A 31-year-old woman presented to the Emergency Department in late spring for 
evaluation of a slowly expanding, pruritic, burning circular red rash on the back of her 
left leg. The rash was accompanied by a flu-like syndrome and temperature to 38.3°C 
(101°F). She recalled that the rash occurred 1 week after hiking in a Pennsylvania State 
Park. On physical examination, an 8-cm diffusely erythematous annular plaque was 
found in the popliteal fossa (Figure 1). An ELISA (enzyme-linked immunosorbent assay) 
titer for Lyme disease (LD) was negative. Because the lesion was not the “classic” bull's 
eye configuration, the physician diagnosed cellulitis and prescribed a 10-day course of 
cephalexin. One week later the patient returned for re-evaluation because the lesion had 
enlarged to 12 cm and her flu-like syndrome persisted. Another physician was consulted 
and recognized that the lesion was consistent with EM and represented early LD. A 10-
day course of doxycycline 100 mg b.i.d. (twice a day) was prescribed and the patient 
improved without incident.  
 
Figure 1. Case illustration, expanding EM in popliteal fossa. 
 
Discussion 
In the United States, the clinical manifestations of LD generally begin 7 to 10 days after 
the bite of a deer tick (Ixodes scapularis or pacificus) infected with Borrelia burgdorferi. 
Most infections with Borrelia burgdorferi are transmitted by the bite of a nymphal stage 
Ixodes scapularis tick. These ticks are round, < 2 mm in size, and have four pairs of legs 
(Figure 2). The epidemiologic setting is generally along the northeast corridor in the late 
spring or early summer. The infected tick must be attached for at least 24–48 h and 
transmits the disease in only 1–3% of bites (1). Stages of LD infection are typically 
defined as early localized, early disseminated, and late chronic. EM is found in most 
patients (60–80%) who develop the early localized form of LD (4). This annular, 
erythematous lesion slowly expands to a maximal diameter of 16 cm. The lesions may be 
asymptomatic, or cause burning, tenderness or pruritus, as in the above case. The rash 
most often occurs at or near the site of the tick bite and, if untreated, persists for 2–3 
weeks. Multiple EMs may occur in 17–50% of cases of early disseminated LD (5). The 
latter represents hematogenous spread of the Borrelia burgdorferi and not the occurrence 
of multiple tick bites.  
 
Figure 2. Different stages of tick life cycle (note infectious nymph second from right). 
 
The EM lesion has been classically described as erythematous with central clearing, the 
so-named “bull's eye” appearance (Figure 3) (4). However, in a study of 118 cases of 
EM, in which Borrelia burgdorferi infection was confirmed by culture or polymerase 
chain reaction, the lesion was homogeneous in 59%, had central erythema in 32% (Figure 
4), and was a “bull's eye” with central clearing in only 9% (2) (Table 1). The punctum 
from the original tick bite is present 30% of the time (Figure 5) (2). EM also may present 
as a vesicular lesion, as documented in 7–8% of patients (Figure 6) (2,6). A conclusion 
that the “bull's eye” EM lesion actually represents a small minority of cases should 
caution clinicians to be wary of the variety of “classic” presentations of EM.  
 Figure 3. “Classic” bull's eye EM, expanding erythema with central clearing (9%). 
 
Figure 4. Diffuse homogeneous EM (50%), central redness (34%). 
Table 1.  
Morphologic Pattern of Erythema Migrans   
Variable presentations Percentage of patients (%) 
Homogeneous 59 
Central erythema 32 
Punctum present 31 
Central clearing, “bull's eye” 9 
Vesicular or ulcerated 7 
 From Smith et al. (2).  
 
Figure 5. Homogeneous EM, with central punctum (30%). 
 
Figure 6. EM with vesicular reaction (9%). 
 
Two-thirds of patients with untreated early LD are at risk of developing early 
disseminated LD, characterized by musculoskeletal, cardiac, or neurologic features. 
Cranial nerve palsies are the most common neurologic manifestation of early 
disseminated LD, particularly in children. More than half of children with neurologic 
symptoms have a facial palsy, which may be bilateral. The palsy can last from several 
days to 2 months. An example of a patient who presented to the Emergency Department 
for a Bell's palsy, subsequently determined to be secondary to LD, is seen in Figure 7. 
The EM can persist in patients with facial palsy and should warrant careful physical 
examination.  
 
Figure 7. Bell's palsy. 
 
Laboratory Testing 
LD must be included in the differential diagnosis when encountering lesions with varying 
characteristics, ranging from spreading erythematous to vesicular lesions. This includes, 
but is certainly not limited to, insect stings, bites, drug eruptions, urticaria, contact 
dermatitis, cellulitis, erythema multiforme, and patients presenting with other annular 
lesions.  
The most widely used studies for LD are antibody detection tests. These should be 
reserved for confirmation of tentative clinical diagnoses that fall in the low to moderate 
pre-test probability category (2, 7). If it is determined that testing is warranted, the 
current recommendation from the Centers for Disease Control is for a two-step testing 
process (8). The first step is to order an ELISA titer; this can be either a total Lyme, or 
separate immunoglobulin G and immunoglobulin M. Only in the case of a positive 
ELISA should the second step, confirmatory Western blot, be ordered (3). Antibody 
testing in patients presenting with EM, as in our case, is not indicated because the rash 
most often develops before the serologic conversion (3). Diagnosis in these cases should 
be made based on clinical acumen. Laboratory testing for early LD should be reserved for 
individuals from endemic areas with manifestations such as prolonged (> 2 weeks) 
unexplained flu-like symptoms without EM (4).  
Treatment 
Treatment for LD should be tailored to the stage of disease and the age of the patient. 
Patients with early acute or early disseminated LD should be treated with a 10- to 21-day 
course of first-line antibiotics. The 21-day course is suggested for those who are 
diagnosed later in the course of illness and with more severe systemic symptoms. 
Doxycycline (100 mg b.i.d.) and amoxicillin (500 mg t.i.d.) have been proven efficacious 
for the treatment of early LD (9-15). Amoxicillin is the treatment of choice in patients 
under the age of 8 years. In cases of allergy or intolerance to these drugs, cefuroxime 
axetil (500 mg b.i.d.) is a suitable substitute and also can be given to nursing mothers (9-
15). Macrolides provide an alternative, but less effective, therapy for patients with allergy 
or intolerance to the preferred regimens. Less than 10% of patients fail to respond to 
antibiotic therapy with doxycycline, amoxicillin, or cefuroxime axetil (9-12). The 
efficacy of doxycycline and amoxicillin are similar, and cefuroxime has been proven to 
be as effective as doxycycline in treatment of patients with early localized Lyme disease 
(9-12). It is important to note that the popular cephalosporin, cephalexin (Keflex), is not 
effective in the treatment of LD, nor are any of the fluoroquinolone class (16, 17) (Table 
2). Treatment is highly effective for LD and patients who complete the recommended 
dose of antibiotics typically see complete resolution of symptoms.  
Table 2.  
Treatment of Early-Stage Lyme Disease (LD)  
Drug Adult dosage Pediatric dosage  Notes 
Doxycycline 100 mg p.o. > 8 years; 1–2 Should not be used for children < 8 years 
Drug Adult dosage Pediatric dosage  Notes 
(Vibramycin, and 
others) 
b.i.d. × 10–21 
days 
mg/kg b.i.d. × 14–
21 days 
old, or for pregnant or lactating women. 
Amoxicillin (Amoxil, 
and others) 
500 mg p.o. 
t.i.d. × 14–21 
days 
25–50 mg/kg/d 
divided t.i.d. × 14–
21 days 
 
Cefuroxime axetil 
(Ceftin) 
500 mg p.o. 
b.i.d. × 14–21 
days 
30 mg/kg/d divided 
b.i.d. × 14–21 days Okay for nursing mothers. 
Azithromycin 500 mg p.o. q.d. × 14 days  
Alternative, but less effective, fourth-line 
therapy for patients with allergies or 
intolerance for preferred regimens. 
Clarithromycin 250 mg p.o. b.i.d. × 14 days 
Erythromycin Should be avoided. A less effective therapy, with some research indicating the potential for microbial resistance. 
Cephalexin (Keflex, 
and others) 
Not effective in the treatment of early LD, should be prescribed with caution 
during the summer months for patients believed to have cellulitis in locations 
where LD is endemic. 
Fluroquinolones Should be avoided, not effective in treatment of early LD. 
p.o. = orally; b.i.d. = twice a day; t.i.d. = three times a day; q.d. = every day.  
Data from Foy and Studdiford (3), Nowakowski et al. (16), and “Treatment of Lyme 
disease” (17). 
 Should not exceed adult dosage.  
 
Conclusions 
In summary, although the incidence of Lyme disease is increasing, it remains an easily 
treatable illness when diagnosed in the early stages. Clinical recognition of the variety of 
“classic” skin lesions representing EM is essential in preventing the potentially 
devastating long-term sequelae of untreated disease.  
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